Scarica l'app Stockscreener
0.6799
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6799
Aprire:
$0.7
Volume 24 ore:
240.98K
Relative Volume:
0.17
Capitalizzazione di mercato:
$2.44M
Reddito:
-
Utile/perdita netta:
$-9.64M
Rapporto P/E:
-0.0982
EPS:
-6.9236
Flusso di cassa netto:
$-10.11M
1 W Prestazione:
-3.72%
1M Prestazione:
-15.54%
6M Prestazione:
-69.51%
1 anno Prestazione:
-66.83%
Intervallo 1D:
$0.68
$0.7016
Intervallo di 1 settimana:
$0.6443
$1.37
Portata 52W:
$0.55
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
Nome
Gt Biopharma Inc
Settore
Industria
Telefono
(800) 304-9888
Indirizzo
505 MONTGOMERY STREET, SAN FRANCISCO
Confronta GTBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.30 | 5.31B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.95 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.60 | 113.25M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2106 | 445.05M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.00 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | ROTH MKM | Buy |
| 2021-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | B. Riley Securities | Buy |
| 2021-03-17 | Iniziato | ROTH Capital | Buy |
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
Tools to assess GT Biopharma Inc.’s risk profile2025 Trading Volume Trends & Stock Timing and Entry Methods - newser.com
Will GT Biopharma Inc. continue its uptrendMarket Growth Report & Fast Momentum Stock Entry Tips - newser.com
GT Biopharma Inc OXIA Stock Analysis and ForecastEconomic Data Impact & Investment Recommendations You Can Trust - earlytimes.in
Chart based analysis of GT Biopharma Inc. trendsStop Loss & Weekly High Potential Stock Alerts - newser.com
Using economic indicators to assess GT Biopharma Inc. potentialMarket Growth Summary & Breakout Confirmation Alerts - newser.com
GT Biopharma Inc. stock volume spike explainedPortfolio Growth Summary & AI Driven Stock Reports - newser.com
Will GT Biopharma Inc. (OXIA) stock test record highs in 2025Quarterly Trade Report & Trade Opportunity Analysis Reports - newser.com
GT Biopharma Inc. stock trend forecastWeekly Profit Report & Fast Moving Market Watchlists - newser.com
Why GT Biopharma Inc. stock is seen as undervaluedPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally - Stocktwits
Visual trend scoring systems applied to GT Biopharma Inc.Market Risk Summary & Long-Term Capital Growth Ideas - newser.com
Using data filters to optimize entry into GT Biopharma Inc.Insider Selling & Consistent Profit Alerts - newser.com
GT Biopharma advances Phase 1 trial of NK cell therapy with no safety issues - Investing.com Nigeria
Stocks In Play: GT Biopharma Inc - Barchart.com
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 - 富途牛牛
GT Biopharma provides enrollment update on GTB-3650 Phase 1 trial in patients with relapsed or refractory (R/R) CD33 expressing hematologic malignancies - MarketScreener
GT Biopharma Reports Successful Phase 1 Trial Progress for GTB-3650 in Hematologic Malignancies - Quiver Quantitative
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 - GlobeNewswire
GT Biopharma Initiates Cohort 3 Dosing; No DLTs, Cohort 4 Planned | GTBP Stock News - Stock Titan
EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Benzinga
GT Biopharma Inc - Menafn.com
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion - MarketScreener
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms - Eastern Progress
Precision Oncology Pipeline Advances from Detection Through Targeted Destruction - The Globe and Mail
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit - GlobeNewswire
Oct 28–29: GT Biopharma CEO Michael Breen to Attend Bahamas Summit; One-on-one Meetings Available - Stock Titan
Key metrics from GT Biopharma Inc.’s quarterly dataBond Market & Weekly Momentum Stock Picks - newser.com
How GT Biopharma Inc. (OXIA) stock reacts to new regulationsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
What’s the recovery path for long term holders of GT Biopharma Inc.Market Volume Summary & Expert Curated Trade Setups - newser.com
What drives GT Biopharma Inc stock priceChart Pattern Recognition & Small Capital Trading Growth - earlytimes.in
Will GT Biopharma Inc. (OXIA) stock profit from automation wave2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
GT Biopharma Inc Stock Analysis and ForecastHead and Shoulders Patterns & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Can swing trading help recover from GT Biopharma Inc. lossesTrade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com
Gt Biopharma Inc Azioni (GTBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
2.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):